Skip to content
Drybench

Drybench Patent.

LASMIDITAN SUCCINATE, NDA 211280

The patents and exclusivities FDA's Orange Book lists for NDA 211280 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.

FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.

Orange Book captured
14 October 2026
Paragraph IV list captured
17 October 2026
Last checked
30 October 2026
Data-branch commit
dadcab56563716abea6c5e31a5e1970080c778ef

Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.

Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.

Open in the appLASMIDITAN SUCCINATE in the molecule app

Listed protection

Listed dates run from 17 Feb 2028 to 6 Jul 2040, each by its own rule; no one date stands for this product.

Earliest listed date
17 Feb 2028US 7,423,050, substance and product and use patentRule R1 · Products 001, 002, 003 · patent.txt lines 12,666, 12,670, 12,673
Latest listed date
6 Jul 2040US 12,071,423, product patentRule R1 · Products 001, 002 · patent.txt lines 12,664, 12,668
Latest substance patent
5 Dec 2037US 11,053,214, substance and product and use patentRule R1 · Products 001, 002, 003 · patent.txt lines 12,663, 12,667, 12,671
Latest listed patent
6 Jul 2040US 12,071,423, product patentRule R1 · Products 001, 002 · patent.txt lines 12,664, 12,668
Latest exclusivity
None listed

9 use-code patents, blocking the coded use only

Products

Each product number FDA lists under NDA 211280, as listed. The sections below name products by these numbers.

  • Product 001 · REYVOW

    Dosage form; route
    TABLET;ORAL
    Strength
    EQ 50MG BASE
    Approval date as listed
    31 Jan 2020
    Type as listed
    DISCN
    Applicant as listed
    ELI LILLY AND CO

  • Product 002 · REYVOW

    Dosage form; route
    TABLET;ORAL
    Strength
    EQ 100MG BASE
    Approval date as listed
    31 Jan 2020
    Type as listed
    DISCN
    Applicant as listed
    ELI LILLY AND CO

  • Product 003 · REYVOW

    Dosage form; route
    TABLET;ORAL
    Strength
    EQ 200MG BASE
    Approval date as listed
    18 Dec 2020
    Type as listed
    DISCN
    Applicant as listed
    ELI LILLY AND CO

Listed patents

Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.

4 entries from 11 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.

  • US 7,423,050, substance and product and use patent

    patent.txt lines 12,666, 12,670, 12,673
    Expiry as listed
    17 Feb 2028
    Rule
    R1
    Flags
    substance · product · use code U-1719
    Product numbers
    001, 002, 003

  • US 12,257,246, use patent

    patent.txt lines 12,665, 12,669, 12,672
    Expiry as listed
    7 Jul 2030
    Rule
    R1
    Flags
    use code U-2718
    Product numbers
    001, 002, 003

  • US 11,053,214, substance and product and use patent

    patent.txt lines 12,663, 12,667, 12,671
    Expiry as listed
    5 Dec 2037
    Rule
    R1
    Flags
    substance · product · use code U-1719
    Product numbers
    001, 002, 003

  • US 12,071,423, product patent

    patent.txt lines 12,664, 12,668
    Expiry as listed
    6 Jul 2040
    Rule
    R1
    Flags
    product
    Product numbers
    001, 002

Listed exclusivities

Each exclusivity FDA lists for NDA 211280, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.

The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 211280.

Paragraph IV list rows giving NDA 211280

The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 211280, each cell as listed.

FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.

The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.

Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.

Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 211280

  • Lasmiditan Succinate · Tablets · 50 mg and 100 mg

    RLD/NDA as listed: Reyvow 211280
    First PIV submission
    31 Jan 2024
    ANDAs
    1
    180-day status
    blank
    Decision posted
    blank
    First applicant approval
    blank
    First marketing
    blank
    Last qualifying patent expiry (as listed by FDA)
    5 Dec 2037

Notes from the trace

  • R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.

Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week